HCC | Clinical

ODAC Opposes Ongoing FDA Approval of Nivolumab for HCC in Patients Pretreated With Sorafenib

April 29, 2021

The FDA’s Oncologic Drug Advisory Committee voted 5 to 4 against the continued accelerated approval of nivolumab for the treatment of patients with hepatocellular carcinoma who were previously treated with sorafenib.

ODAC Unanimously Supports Continued Approval of Pembrolizumab for HCC in Sorafenib-Pretreated Patients

April 29, 2021

In an 8 to 0 vote, the FDA’s Oncologic Drug Advisory Committee opted to continue to accelerated approval of pembrolizumab for the treatment of patients with hepatocellular carcinoma who have been previously treated with sorafenib.

Systemic Therapy for Advanced Hepatocellular Carcinoma: ASCO Guidelines

April 17, 2021

In the past 3 years, the FDA has approved 7 novel drugs, either given alone or in combination, to help treat patients with hepatocellular carcinoma.

LEGACY Trial of Radioembolization Shows Practice-Changing Data in HCC

April 06, 2021

Michael R. Charlton, MD, MBBS, discusses the impact of the LEGACY trial investigating yttrium-90 radioembolization in patients with solitary, unresectable hepatocellular carcinoma.

Regorafenib/Nivolumab Proof of Concept Suggested in Third-Line, Refractory HCC

March 28, 2021

Half of all patients with hepatocellular carcinoma treated with the combination of regorafenib and nivolumab following progression on 2 lines of chemotherapy achieved disease control, according to initial results from a phase 2 proof-of-concept trial.

Sintilimab With SBRT Leads to 100% Disease Control in Oligometastatic HCC

March 25, 2021

In a single-arm study, 100% of patients treated with sintilimab plus stereotactic body radiotherapy who had oligometastases of hepatocellular carcinoma achieved disease control and were alive and progression free at 6 months.

FDA Approves TheraSphere Y-90 Glass Microspheres for Unresectable HCC

March 18, 2021

The FDA has approved TheraSphere yttrium-90 glass microspheres for the treatment of patients with unresectable hepatocellular carcinoma.

Looking Beyond Atezolizumab/Bevacizumab for the Treatment of HCC

March 10, 2021

In an interview with Targeted Oncology, Laura Goff, MD, discussed the treatment of hepatocellular carcinoma in the frontline and beyond.

How Real-World Regorafenib Dosing Correlates With Prior Sorafenib Treatment in HCC

March 09, 2021

Richard Finn, MD, discusses the interim results of the REFINE Study, which tests the real-world dosing of regorafenib in patients with unrespectable hepatocellular carcinoma.

Doctors Debate: Is Systemic or Liver-Directed Therapy Best for Hepatocellular Carcinoma?

March 05, 2021

As part of the virtual 17th Annual Meeting of the International School of Gastrointestinal Oncology, a debate ensued around whether liver-directed or systemic therapy is best for the treatment of patients with HCC.